Immucor, Inc. (BLUD), a manufacturer of diagnostic substances, Wednesday reported a marginal rise in earnings for the fourth quarter on higher sales, partly offset by increase in costs and expenses.
The Norcross, Georgia-based company's net income for the fourth quarter was $18.3 million, marginally up from $18.2 million in last year quarter. On a per share basis, earnings remained flat at $0.26. On average, five analysts polled by First Call/Thomson Financial projected earnings of $0.23 per share.
Net sales for the fourth quarter were $68.6 million, 12% higher than $61.1 million in the same quarter a year before. Five analysts, on average, anticipated the company to report revenues of $67.36 million.
Income from operations grew to $28.2 million from $27.4 million in the same quarter of the previous year.
Gross profit for the fourth quarter was $49.4 million, up from $45.0 million in the comparable quarter of the prior year.
Total operating expenses rose to $21.2 million from $17.6 million in the same quarter of the earlier year. Provision for income taxes grew to $10.5 million from $10.0 million in the year-ago quarter.
For the fiscal year 2008, the company's net income was $71.5 million or $1.00 per share, up from $60.1 million or $0.85 per share in the earlier year. Five analysts, on average, expected earnings of $0.98 per share.
Net sales for the fiscal year were $261.2 million, higher than $223.7 million in the preceding year. Five analysts' average revenue projection was $259.94 million.
Immucor's stock closed Wednesday's regular trading session at $29.15, down 34 cents or 1.15% on a volume of 1.06 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.